LA JOLLA, Calif., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to present an overview of the company at three upcoming investor conferences.
- Leerink Partners 6th Annual Global Healthcare Conference, New York, February 16, 2017 at 9:30 a.m. EST (6:30 a.m. PST)
- Cowen and Company 37th Annual Healthcare Conference, Boston, March 8, 2017 at 9:20 a.m. EST (6:20 a.m. PST)
- Oppenheimer 27th Annual Healthcare Conference, New York, March 21, 2017 at 1:35 p.m. EDT (10:35 a.m. PDT)
A live audio webcast and replay of each presentation will be available in the Investors section of Kura Oncology's website at www.kuraoncology.com.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology’s lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials. The pipeline includes KO-947, an ERK inhibitor, and KO-539, an inhibitor of the menin-MLL protein-protein interactions. For additional information about Kura Oncology, please visit the company’s website at www.kuraoncology.com.